Concerns about off-label use drove most of the votes against approval during the the US FDA's Bone, Reproductive and Urologic Drugs Advisory Committee's review of Clarus Therapeutics Inc.'s oral testosterone candidate Jatenzo (testosterone undecanoate) on Jan. 9
Many panel members were sympathetic to the need for an oral therapy for those who would fit the indication, which...





